MARKET NEWS

LexaGene Detects a Slow-Growing Bacterium at Least 36-Times Faster Than Conventional Methods With Potential to Increase Vaccine Safety & Supply
Enterprise Therapeutics Doses First Subjects in Phase 1 Trial for Novel Cystic Fibrosis Therapy  
Inceptor Bio Launches Next-Generation CAR-T, CAR-M, & NK/NKT Platform Focused on Advancing Cell & Gene Therapies to Cure Difficult-to-Treat Cancers
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line & Beyond HNSCC
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 & Two Prominent SARS-CoV-2 Variants

  FEATURED EDITORIAL

  COMPANY PROFILE

Emergent CDMO is dedicated to helping pharma and biotech innovators bring lifesaving therapies to patients from around the world. Our nine development and manufacturing sites in North America and Europe can support early to late stage production of biotherapeutics and vaccines. Whether you’re looking for initial process development support, small volumes of material for clinical trials, or large-scale production for a global commercial therapy, our experienced CDMO team is ready to serve as your trusted guide from molecule to market. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy

Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy

Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs)…..

Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement With Gilead Sciences

Jounce Therapeutics Achieves First Milestone in Exclusive License Agreement With Gilead Sciences

Jounce Therapeutics, Inc. recently announced the US FDA clearance of its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences, Inc. has exclusive rights….

iTeos Therapeutics & GSK Announce Development & Commercialization Collaboration 

iTeos Therapeutics & GSK Announce Development & Commercialization Collaboration 

iTeos Therapeutics and GlaxoSmithKline plc recently announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody currently in Phase 1 development as a….

VERAXA Biotech & Quadira Biosciences Enter Partnership on ADC Development

VERAXA Biotech & Quadira Biosciences Enter Partnership on ADC Development

VERAXA Biotech GmbH recently announced it has entered into a partnership agreement with Quadira Biosciences AG, Zug, Switzerland, to jointly develop a suite of novel ADCs for the….

Liminatus Pharma R&D Consortium Companion Diagnostic YN 1203 Demonstrates ~70% Sensitivity & Specificity in Clinical Testing

Liminatus Pharma R&D Consortium Companion Diagnostic YN 1203 Demonstrates ~70% Sensitivity & Specificity in Clinical Testing

Liminatus Pharma recently announced its companion diagnostic to support checkpoint inhibitor therapies, YN1203 CDx liquid biopsy test (YN1203 ELISA Kit), has demonstrated….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 30 – Drug Delivery
July 7 – Prefilled Syringes